In this study, researchers describe programmable T cell engagers (PTEs), a novel class of agents created with DNA origami, a nanotechnology that allows the precise spatial arrangement of biomolecules. When combined with antibodies, this approach holds great promise to develop specific and effective biomedical nanotherapies for diseases like cancer.

Through the use of Revvity’s IVIS™ Lumina X5 optical system’s high-throughput and high-sensitivity capabilities to assess therapy targeting and biodistribution in a mouse leukemia model as well as flow cytometry studies using BioLegend antibodies to further validate the specificity of their novel PTE technology, the team showed that PTE’s functioned and distributed in vivo demonstrating the mechanism of action within living animals. PTEs were also shown to control tumor outgrowth.

For research use only. Not for use in diagnostic procedures.